ClinicalTrials.gg

Program

efruxifermin

Also written as “Efruxifermin” and “AMG 876”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 3, since Nov 22, 20236 company-led studies, 3 open or runningNext primary completion: Feb 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk43 open or runningphase 3since Nov 22, 2023Feb 16, 2021Feb 2030phase 3 · NCT06528314
Amgen20 open or runningphase 1since Sep 28, 2011Sep 28, 2011none ahead
  • Named in Novo Nordisk’s own pipeline as Efruxifermin in MASH, phase 3, as of Nov 5, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2011First study: phase 1 study in Diabetes MellitusNew to AmgenAmgen · NCT01492465 · 47 enrolled · United States
  2. Mar 25, 2013Phase 1 study in Diabetes MellitusAmgen · NCT01856881 · 86 enrolled · United States
  3. Feb 16, 2021Novo Nordisk's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Novo NordiskNovo Nordisk · NCT04767529 · 128 enrolled · United States, Puerto Rico
  4. Nov 22, 2023Phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06161571 · 700 enrolled · United States, Argentina, Australia and more
  5. Dec 6, 2023Phase 3 study in NASH With FibrosisNovo Nordisk · NCT06215716 · 1,650 planned · United States, Argentina, Australia and more
  6. Jun 28, 2024Phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06528314 · 2,150 planned · United States, Argentina, Australia and more

Ahead

  1. Feb 2030Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06528314
  2. Feb 2033Primary completion: phase 3 study in NASH With FibrosisNovo Nordisk · NCT06215716

TargetBeta

“A long-acting bivalent analog of fibroblast growth factor 21 (FGF21) and fusion protein composed of human immunoglobulin G1 (IgG1) Fc domain attached to a modified form of FGF21, with metabolic regulating, anti-diabetic, and anti-fibrotic activities. Upon administration, efruxifermin mimics FGF21…”NCIt, read by Claude

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
efimosfermin alfaGlaxoSmithKlinephase 310
pegozafermin89bio-incphase 38
zalferminNovo Nordiskphase 210

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06528314Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingNovo NordiskFeb 20302,150
NCT06215716NASH With Fibrosis · United States, Argentina, Australia and more3RecruitingNovo NordiskFeb 20331,650
NCT06161571Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3Active, not recruitingNovo NordiskMar 3, 2026700
NCT04767529Non-alcoholic Fatty Liver Disease · United States, Puerto Rico2CompletedNovo NordiskMay 2, 2024128
NCT01856881Diabetes Mellitus · United States1TerminatedAmgenNov 201486
NCT01492465Diabetes Mellitus · United States1TerminatedAmgenJul 201247

How it is read

Names in the registry

  • “Efruxifermin”, 4 entries
  • “AMG 876”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.